SenzaGen AB vinner och går direkt in på 33-listan!

SenzaGen AB kammade hem vinsten vid 33-listans regionala final i Lund. Detta innebär direkt en plats på årets upplaga av Ny Teknik och Affärsvärldens lista över landets 33 hetaste unga teknikbolag.

SenzaGens produkter ersätter djurförsök för allergitester. EU har infört ett förbud mot att testa kosmetika på djur och en helt ny marknad skapas. Senzagen har redan utvecklat ett testalternativ som bygger på genanalys i mänskliga celler.

Efter en grillning av juryn och en slagkraftig pitch meddelades det att SenzaGen stod som segrare och får en direkt plats på årets 33-lista.

– Detta känns helt fantastiskt! Det är ett kvitto från både publiken och juryn på det vi redan är övertygande om inom SenzaGen dvs att vi kommer att vara ledande för att ersätta djurförsök, först inom kosmetikabranschen, men så småningom också inom andra branscher, säger VD Anki Malmborg Hager.

SenzaGen startade 2010 som ett spin-out bolag från institutionen för Immunteknologi, men det är först de senaste månaderna som verksamheten tagit fart på allvar. Bolaget har flyttat ut från Lunds Universitet till lokaler på Medicon Village, tagit in finansiering och anställt egen personal. Senzagens första produkt, ett test för hudöverkänslighet för kemikalier, säljs redan till vissa utvalda kunder. Bolaget arbetar nu mot en ny generation av produkter som adresserar andra typer av överkänslighet och andra exponeringsvägar. Baserad på efterfrågan från marknaden ökar nu Senzagen kommersialiseringsåtgärderna för lansering av framtida produkter.

Här hittar ni NyTekniks artikel: http://www.nyteknik.se/33listan/article3889772.ece

Om 33-listan

33-listan bygger på nomineringar av företag från hela Sverige och vinnarna utses gemensamt av redaktionerna på Ny Teknik och Affärsvärlden. Juryn letar efter företag med en unik produkt eller tjänst uppbyggd kring en tydlig innovation med stor internationell potential – en innovation som har förutsättningar att förändra spelreglerna i sin bransch. För att platsa på listan måste företaget vara baserat i Sverige max 7 år gammalt. Mer och påhttp://www.33-listan.se

För intervju och vidare information vänligen kontakta:

Anki Malmborg Hager, 0768-284 822, amh@senzagen.com

SenzaGen AB, www.senzagen.com

Ny Teknik & Affärsvärlden list SenzaGen AB as one of the 33 most promising young innovative companies in Sweden

On Tuesday, SenzaGen AB achieved a position on the so called 33-list in Sweden after winning Lund local elevator pitch for NyTeknik and Affärsvärlden 33-list.

On Tuesday, SenzaGen AB achieved a position on the so called 33-list in Sweden after winning Lund local elevator pitch for NyTeknik and Affärsvärlden 33-list.

After several interviews by the organisers, a challenging questioning by an initiated jury and a smashing elevator pitch, Senzagen acquired a position on the renowned 33-list.

The 33-list is based on propositions of companies from all over Sweden and the winners are chosen collectively by the editorial staff at the two journals Ny Teknik and Affärsvärlden. The jury is looking for companies with a unique product or service based on a clear innovation with great international potential – an innovation with the ability to change the rules in the business. To qualify for a position on the list, the company must be based in Sweden and be less than 7 years. Read more on (in Swedish) http://www.33-listan.se 

Link to the article in Ny Teknik 2015, March 2: http://www.nyteknik.se/33listan/article3889772.ece (Swedish)

For more information
Anki Malmborg Hager, 0768-284 822, amh@senzagen.com
SenzaGen AB, www.senzagen.com

Maria Agemark ny kvalitetsansvarig på SenzaGen

​SenzaGen är i en expansiv fas och tar in förstärkning. Maria Agemark anställs som kvalitetsansvarig och kommer närmast från avdelningen Immunteknologi på LTH. Maria har en doktorsexamen i biokemi där hon forskade på Aquaporiner hos människa och växter.

SenzaGen är i en expansiv fas och tar in förstärkning. Maria Agemark anställs som kvalitetsansvarig och kommer närmast från avdelningen Immunteknologi på LTH. Maria har en doktorsexamen i biokemi där hon forskade på Aquaporiner hos människa och växter.

– Det ska bli väldigt roligt och utmanande att jobba i ett nytt företag som befinner sig i en spännande fas. Jag känner väl till forskningen bakom produkterna och ser fram emot att ingå i det nya teamet som SenzaGen håller på att bygga upp, säger Maria Agemark.

Maria börjar på SenzaGen i mars 2015 och kommer att fokusera på att bygga upp labbet och kvalitetssystemet.

– Maria har en kompetens som vi har ett stort behov av för att ta bolaget till nästa nivå. Jag ser mycket fram emot att arbeta tillsammans med Maria, säger Anki Malmborg Hager, VD på SenzaGen.

SenzaGen AB completes successful collaboration with Beiersdorf

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the successful completion of a collaboration with Beiersdorf.

SenzaGen AB, a diagnostic company working to replace animal testing, has been collaborating with Beiersdorf to evaluate its skin sensitization test for chemicals.

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the successful completion of a collaboration with Beiersdorf.

SenzaGen AB, a diagnostic company working to replace animal testing, has been collaborating with Beiersdorf to evaluate its skin sensitization test for chemicals.

SenzaGen AB is based on research at the Department of Immunotechnology at Lund University, providing animal-free, in vitro sensitization tests for the cosmetic, chemical, pharmaceutical and food industries.

Beiersdorf has been working in the development and recognition of alternative methods for more than 20 years and is one of the main players in the cosmetic industry in Europe. An industry that is highly interested in recommendations in this field – especially after the ban in March 2013 on animal testing in the cosmetic industry.

“It has been very valuable for SenzaGen to be able to challenge its skin sensitization test in an industrial setting.” says Prof. Carl Borrebaeck, chairman of the board of SenzaGen.

In the collaboration, blind testing of two industrial test sets of chemicals were performed using the SenzaGen proprietary GARD assay, resulting in an accuracy of 89%.

www.senzagen.com

For more information please contact:

Carl Borrebaeck, Chairman of the Board, SenzaGen AB
carl.borrebaeck@immun.lth.se

+46 708 218330

SenzaGen AB completes successful collaboration with Beiersdorf

SenzaGen AB completes successful collaboration with Beiersdorf

2014-11-19, Lund, Sweden

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the successful completion of a collaboration with Beiersdorf.

SenzaGen AB, a diagnostic company working to replace animal testing, has been collaborating with Beiersdorf to evaluate its skin sensitization test for chemicals.

SenzaGen AB is based on research at the Department of Immunotechnology at Lund University, providing animal-free, in vitro sensitization tests for the cosmetic, chemical, pharmaceutical and food industries.

Beiersdorf has been working in the development and recognition of alternative methods for more than 20 years and is one of the main players in the cosmetic industry in Europe. An industry that is highly interested in recommendations in this field – especially after the ban in March 2013 on animal testing in the cosmetic industry.

“It has been very valuable for SenzaGen to be able to challenge its skin sensitization test in an industrial setting.” says Prof. Carl Borrebaeck, chairman of the board of SenzaGen.

In the collaboration, blind testing of two industrial test sets of chemicals were performed using the SenzaGen proprietary GARD assay, resulting in an accuracy of 89%.

About SenzaGen

SenzaGen AB is an early-phase diagnostics company based on strong research and know-how of the immune system and its reaction to hazardous agents, such as irritants and allergens. The company’s products are genetic tests for sensitizing agents, which have been designed based on how indicator cells react when exposed to a variety of chemicals.

SenzaGen AB was created to meet the international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development. SenzaGen AB services will offer the most accurate, animal-free in vitro testing option for manufacturers of cosmetics, chemicals, food, and pharmaceuticals.

SenzaGen AB is a spin-off company founded by researchers at Lund University to bring academic results to good use for society. The company is situated in facilities at Medicon Village, Lund, Sweden.

www.senzagen.com

For more information please contact:

Carl Borrebaeck, Chairman of the Board, SenzaGen AB

carl.borrebaeck@immun.lth.se

+46 708 218330

LU Innovation System investerar i bolag som ersätter djurförsök

Senzagen AB, ett diagnostikbolag som jobbar mot att ersätta djurförsök, baseras på forskning från Lunds universitet. Senzagen tillhandahåller överkänslighetstester för kosmetisk, kemisk, farmaceutisk och livsmedelsindustri.
LU Innovation System AB har sedan 1999 investerat i drygt 70 nya forskningsbolag från Lunds universitet. Nu kommer även Senzagen AB att ingå i portföljen.

Pressmeddelande 2014.11.17

LU Innovation System investerar i bolag som ersätter djurförsök

Senzagen AB, ett diagnostikbolag som jobbar mot att ersätta djurförsök, baseras på forskning från Institutionen för Immunteknologi vid Lunds universitet. Senzagen tillhandahåller överkänslighetstester för kosmetisk, kemisk, farmaceutisk och livsmedelsindustri.

LU Innovation System AB har sedan 1999 investerat i drygt 70 nya forskningsbolag från Lunds universitet. Nu kommer även Senzagen AB att ingå i portföljen.

– Vi har stark anknytning till Lunds universitet och investeringen från LU Innovation System AB bekräftar vårt arbete och bidrar till att vi kan ta nästa viktiga steg i vår kommersialiseringsstrategi, säger Anki Malmborg, vd på Senzagen AB.

– Vi är mycket glada över att bli delägare i Senzagen, som vi tror har en mycket stor affärsmässig potential – att sedan deras teknologi kan ersätta djurförsök gör ju inte saken sämre, säger Linus Wiebe, innovationsdirektör vid Lunds universitet och vd för LU Innovation System AB.

Senzagens första produkt, ett hudöverkänslighetstest för kemikalier, finns redan på marknaden. Bolaget arbetar nu mot en ny generation av produkter som adresserar andra typer av överkänslighet och andra exponeringsvägar. Baserad på efterfrågan från marknaden ökar nu Senzagen kommersialiseringsåtgärderna för lansering av framtida produkter. Läs gärna mer på: www.senzagen.com

För intervju och vidare information vänligen kontakta:

SenzaGen AB, Anki Malmborg, 0768-284 822

LU Innovation System AB, Linus Wiebe, 0733- 451 240 eller undertecknad

Malinee GranhofCommunication Manager LU Innovation System Sölvegatan 16 | SE-223 62 Lund

P.O. Box 117 | 221 00 Lund, Sweden
Telephone: 046-222 12 84

Mobile: 070-695 88 48
www.innovation.lu.se

SenzaGen AB has attracted support from LU Innovation System AB to promote commercialization

SenzaGen AB announces that LU Innovation System AB (LUIS) invests in the company.

Press release

SenzaGen AB has attracted support from LU Innovation System AB to promote commercialization

2014-11-17, Lund, Sweden

SenzaGen AB announces that LU Innovation System AB (LUIS) invests in the company.

SenzaGen AB, a diagnostic company working to replace animal testing, is based on research at the Department of Immunotechnology at Lund University. The company provides in vitro sensitization tests for the cosmetic, chemical, pharmaceutical and food industries.

LU Innovation System AB (LUIS) has since 1999 been involved in spinning out 69 companies based on research from Lund University. The portfolio has now increased by the investment in SenzaGen AB.

“We have a strong connection to Lund University and the investment by LUIS acknowledges our work and provides us with the ability to take the next important steps in our commercialization strategy,” says Anki Malmborg Hager, CEO of SenzaGen AB.

“We are very pleased of being a partner in Senzagen, which we believe has a great commercial potential. The fact that their technology can replace animal experiments doesn´t make it worse”, says Linus Wiebe, Innovation Director Lund University and CEO LU Innovation System.

The company´s first product, a skin sensitization test of chemicals, is already on the market, and the company is working on next generation products that will address other types of sensitizers and other routes of exposure. Based on the demand from the market the company is now gearing up its commercial operations and prepares for the launch of further products.

About SenzaGen

SenzaGen AB is an early-phase diagnostics company based on strong research and know-how of the immune system and its reaction to hazardous agents, such as irritants and allergens. The company’s products are genetic tests for sensitizing agents, which have been designed based on how indicator cells react when exposed to a variety of chemicals.

SenzaGen AB was created to meet the international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development. SenzaGen AB services will make in vitro testing a real option for manufacturers of cosmetics, chemicals, food, and pharmaceuticals.

SenzaGen AB is a spin-off company founded by researchers at Lund University to bring academic results to good use for society. The company is situated in facilities at Medicon Village, Lund, Sweden.

www.senzagen.com

For more information please contact:

Anki Malmborg Hager, CEO, SenzaGen AB

amh@senzagen.com

+46 768 284822

Linus Wiebe, Director of Innovation, LU Innovation Systems AB

linus.wiebe@innovation.lu.se

0733- 451 240

Dr. Henrik Johansson, scientist and COO of SenzaGen AB, was awarded the LUSH Young Researcher Award 2014.

"The project for which Dr. Johansson was awarded, the Lush Prize Young Researcher Award, describes the development and use of the novel test method GARD – Genomic Allergen Rapid Detection, an assay for assessment of chemical sensitizers.

…GARD utilises an in vitro model of so-called dendritic cells, a central player in the human immune system. These cells are stimulated with any substances to be tested, and following an incubation time of 24h, the genetic material of the cells are isolated. By measurements of a certain set of genes in the cells, which could be viewed as on/off-switches of the immune response, the eventual risk of the tested substances ability to induce allergy can be predicted.” [Lush Prize Young Researcher http://www.lushprize.org/2014-prize/2014-prize-winners/]

Read more on Lush Prize Young Researcher Award web site

For more information please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
anki.malmborg.hager@senzagen.com
+46 768 284822

SenzaGen AB continues to gear up its operations

SenzaGen AB, a diagnostic spin-off company from Lund University, announces that Dr Carl-Henric Nilsson and Ann Gidner will join the board of directors.

2014-11-12, Lund, Sweden

SenzaGen AB, a diagnostic spin-off company from Lund University, announces that Dr Carl-Henric Nilsson and Ann Gidner will join the board of directors.

SenzaGen AB, a diagnostic company working to replace animal testing, recently announced the recruitment of Dr. Anki Malmborg Hager as CEO. The company now continues to recruit top level associates and hereby announces that Dr Carl-Henric Nilsson and Ann Gidner will join the board.

SenzaGen AB is based on research at the Department of Immunotechnology at Lund University, providing animal-free, in vitro sensitization tests for the cosmetic, chemical, pharmaceutical and food industries.

“We are entering into a very exciting commercial phase and are happy to be able to engage board members with international experience from our target markets,” says Prof. Carl Borrebaeck, chairman of the board of SenzaGen.

Carl-Henric Nilsson holds a PhD and M.Sc. in Industrial management, and is Associate Professor at Lund University, School of Economics and Management. He is CEO of Kunskapspartner AB, Chairman of Kunskapspartner Holding AB, Boardmember in FX International AB and Boffins Holding AB. Carl-Henric’s research is focused on Business development and Industrialization with numerous scientific publications. Carl-Henric is working with entrepreneurs on a global basis with a broad contact net, especially in China and the United States.

Ann Gidner holds a Master of Science in Chemical Engineering /Bioprocessing and a Bachelor in Business Administration. She has extensive international experience from the chemical industry with global leading positions in e.g. Cambrex and Lanxess Corporations. Furthermore, she has held managing positions in RFR Solutions AB, Semcon Caran AB, and Monocl AB. She is currently Director of Sales & Business Development Europe at Novozymes Biopharma, Copenhagen.

Other members of the board are chairman Carl Borrebaeck and deputy Malin Lindstedt.

About SenzaGen

SenzaGen AB is an early-phase diagnostics company based on strong research and know-how of the immune system and its reaction to hazardous agents, such as irritants and allergens. The company’s products are genetic tests for sensitizing agents, which have been designed based on how indicator cells react when exposed to a variety of chemicals.

SenzaGen AB was created to meet the international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development. SenzaGen AB services will offer the most accurate, animal-free in vitro testing option for manufacturers of cosmetics, chemicals, food, and pharmaceuticals.

SenzaGen AB is a spin-off company founded by researchers at Lund University to bring academic results to good use for society. The company is situated in facilities at Medicon Village, Lund, Sweden.

www.senzagen.com

For more information please contact:

Carl Borrebaeck, Chairman of the Board, SenzaGen AB

carl.borrebaeck@immun.lth.se

+46 708 218330

SenzaGen AB recruites Anki Malmborg Hager as CEO

SenzaGen AB, a diagnostic spin-off company from Lund University, announces the that Dr Anki Malmborg Hager will take the position as CEO for the company.

SenzaGen AB, a diagnostic spin-off company from Lund University, announces the that Dr Anki Malmborg Hager will take the position as CEO for the company.

SenzaGen AB is a diagnostic company working to replace animal testing. There is an increasing international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development. SenzaGen offers such a choice and its products are in vitro based tests accurately determining the sensitization ability of substances.

SenzaGen AB is based on research at the Department of Immunotechnology at Lund University conducted by Assoc. Prof. Malin Lindstedt and coworkers.

“The 2013 ban on animal testing in the cosmetic industry provides Senzagen with an optimal opportunity to launch many years of research into society and enter a commercial phase of our products,” says Assoc. Prof. Malin Lindstedt.

The company´s first product, a skin sensitization test of chemicals, is already on the market, and the company is working on next generation products that will address other types of sensitizers including other routes of exposure.

Based on the demand from the market the company is now gearing up its commercial operations and the first step is to recruit an experienced CEO.

“We are very happy to have been able to recruit Dr. Malmborg, who has extensive experience from commercialization of academic results, financial markets and business developments says Prof.Carl Borrebaeck, chairman of the Board of SenzaGen.

Anki Malmborg Hager has more than 20 years´ experience in both pharmaceutical and biotech companies that are spin-offs from the University. She held the position as Investment Director in Lund University Bioscience AB between 2009 and 2011 as well as management positions in eg. Alligator Bioscience AB, XImmune AB (CEO), Cantargia AB (CEO), and Diaprost AB (CEO).

“I am very pleased to have been offered this opportunity” says Anki Malmborg Hager. “The underlying research in SenzaGen is world class and the market window of opportunity is timely and very exciting. I am looking forward to joining the SenzaGen team and to lead the next steps in the commercialization of many years of first-class research”.


For more information please contact:

Carl Borrebaeck, Chairman of the Board, SenzaGen AB

carl.borrebaeck@immun.lth.se

+46 708 218330